A Research on a new cancer vaccine is now developed in the US which only selects particular genetic errors in the tumor of a patient . It showed in the tests on three patients the possibility of directing the immune system to fight skin cancers.
Although the American team admits it is still too soon to make final conclusions on the results , it would still mark a “significant step” concerning its research on the customized cancer vaccines. The Charity Cancer Research in UK commented and called the test an “ exciting but very early-stage trial”
It is known that the UV light may convert healthy skin cells into deadly melanomas by destroying the DNA. Tumors contain hundreds of undetected mutations that are uniquely present in every patient . The mutations can alter the proteins that becomes visible at the surface of cells and appear like identifying flags .
The team who are based in St Louis and Oklahoma for the most part, examined the genetic mutations to anticipate the new and special flags that would be flown by the cancer cells. The new flags which is known as neoantigens are then examined by a computer algorithm to determine which are perfect targets for such vaccine .
A volunteer patient was said to be in remission and had been cancer free , another one still has the tumor yet remained stable, the third patients tumor had reduced in size in the months after the vaccine was given until it returned to its original size ad remained unchanged. At this point, the team are still examining particularly on the safety of the vaccine and trying to determine if it stimulates an immune response. The result came out successful on both tests.
“This exciting but very early-stage trial shows that it may be possible to create vaccines that are tailored to the specific genetic mistakes in a patient’s cancer. “ Dr Alan Worsley said , of the Cancer Research UK.
“At the moment it’s not clear how effective this immunotherapy would be at killing cancer cells in the body and improving survival, but this promising study sets the stage for creating vaccines that are designed to target each patient’s individual tumor in the future.”